Overview

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2021-08-31

Target enrollment:

Participant gender:

Summary

This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body.

Phase:

Phase 3

Details

Lead Sponsor:

Alliance for Clinical Trials in Oncology

Collaborators:

Astellas Pharma US, Inc.
Biologics, Inc.
Medivation, Inc.
National Cancer Institute (NCI)

Treatments:

Prednisone